Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent chemoradiotherapy with cisplatin/carboplatin plus Iparomlimab and Tuvonralimab as adjuvant therapy in postoperative high‑risk cervical cancer
ChiCTR2500115098Phase 4Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab and tuvonralimab in Cervical Cancer (CC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Disease-free survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500115098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115098.